GLOBAL LIVER INSTITUTE
Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most common liver disease in the world – nonalcoholic fatty liver disease (NAFLD) – and it’s more severe form, nonalcoholic steatohepatitis (NASH).
How do you plan to #StepUpforNASH? Learn more about how you can get involved today!
Despite acknowledging OCA met the endpoint established by the FDA of reducing fibrosis by at least one stage, GIDAC voted against approval for treatment for NASH.
It is more crucial than ever to not only understand the latest developments in the field but also play an active role in them.
At GLI, we believe in creating solutions for patients at every stage of their care pathway.
Let’s Step Up for NASH this June and raise awareness about nonalcoholic fatty liver disease (NAFLD) and its more advanced form, nonalcoholic steatohepatitis (NASH), in your communities.
With the NASH horizon full of new developments, it is important to maintain focus on high-quality, affordable, and equitable care for patients with NAFLD and NASH.
In an effort to manage this growing disease, the AGA, AACE and AASLD developed evidence-based clinical practice guidelines that highlight recommendations for screening, diagnosis and management of NAFLD and NASH.
With NASH drug approval in the US on the horizon, energy has been high throughout the field. Nevertheless, we still face challenges – regulatory science must be aligned, and advocacy among stakeholders must be employed to help patients understand what to expect once we enter this new stage of NASH treatments.
People living with NASH, patients and families, whose lives and livelihoods are at risk from a liver disease few outside of a small circle of academic and clinical experts had heard of a few years...
In 2021, GLI NASH Council partners collaborated to draft this set of actionable recommendations for the full spectrum of stakeholders involved in NASH prevention and treatment, including: patients and caregivers, clinicians, patient advocacy organizations, medical societies, industry…
I had the opportunity to participate in the NASH-TAG 2022 Conference in Park City, Utah. Thank you to course directors Michael Charlton, MBBS, FRCP; Vlad Ratziu, MD; Stephen Harrison, MD, and Rohit Loomba, MD, MHSc for setting a standard for high-quality scientific presentations, and even higher expectation and tone for collaboration and innovative thinking…
